ASTRAZENECA PHARMA IND LT (ASTRAZEN) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-0.80%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 2.7%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 23.3%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹6,236.31

200-Day DMA ● Overlay

₹5,783.94

14-Day RSI ● Overlay

49.2 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹15,078 Cr

Large cap

Stock P/E (TTM) Valuation

86.9x

Price / EPS

Book Value (₹) Assets

₹349.0

P/B: 17.2x

ROE (%) Quality

23.3%

Net Profit / Equity

ROCE (%) Efficiency

29.3%

EBIT / Capital

Dividend Yield Yield

0.60%

Face Value: ₹10

Debt / Equity Solvency

0.13x

Manageable

EPS (TTM) Per Share

₹69.16

Trailing 12M

OPM (%) Spread

9.0%

EBITDA Margin

Free Cash Flow Cash

-₹18.00 Cr

CFO - Capex

About ASTRAZENECA PHARMA IND LT

ASTRAZENECA PHARMA IND LT (ASTRAZEN) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 6.5% × Turnover: 0.85x × Leverage: 1.13x = ROE: 23.3%

✓ Company Strengths (Pros)

• Company has maintained a healthy low debt-to-equity ratio of 0.13.
• Company has a stellar track record of return on equity (ROE of 23.3%).

⚠ Key Considerations & Risks (Cons)

• Stock is trading at a premium of 17.2x its book value.
• Commanding an elevated valuation multiple with P/E at 86.9x.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹2,432 Cr

Latest PAT

₹170.00 Cr

EPS (TTM)

₹69.16

OPM %

9.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹295.00 Cr	₹311.00 Cr	₹306.00 Cr	₹383.00 Cr	₹388.00 Cr	₹408.00 Cr	₹440.00 Cr	₹480.00 Cr	₹526.00 Cr	₹559.00 Cr	₹612.00 Cr	₹579.00 Cr	₹683.00 Cr
Operating Profit (EBITDA)	₹67.00 Cr	₹53.00 Cr	₹15.00 Cr	₹49.00 Cr	₹38.00 Cr	₹53.00 Cr	₹77.00 Cr	₹86.00 Cr	₹81.00 Cr	₹75.00 Cr	₹45.00 Cr	₹61.00 Cr	₹49.00 Cr
OPM %	23.0%	17.0%	4.9%	13.0%	10.0%	13.0%	17.0%	18.0%	15.0%	13.0%	7.0%	11.0%	7.0%
Interest Expense	₹0 Cr	₹0 Cr	₹1.00 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹1.00 Cr	₹1.00 Cr	₹1.00 Cr	₹1.00 Cr	₹2.00 Cr	₹2.00 Cr
Depreciation	₹4.00 Cr	₹4.00 Cr	₹4.00 Cr	₹4.00 Cr	₹4.00 Cr	₹9.00 Cr	₹9.00 Cr	₹18.00 Cr	₹17.00 Cr	₹3.00 Cr	₹4.00 Cr	₹6.00 Cr	₹5.00 Cr
Profit before Tax (PBT)	₹71.00 Cr	₹73.00 Cr	₹20.00 Cr	₹54.00 Cr	-₹15.00 Cr	₹51.00 Cr	₹42.00 Cr	₹78.00 Cr	₹75.00 Cr	₹73.00 Cr	₹47.00 Cr	₹58.00 Cr	₹51.00 Cr
Net Profit (PAT)	₹54.00 Cr	₹52.00 Cr	₹16.00 Cr	₹39.00 Cr	-₹12.00 Cr	₹38.00 Cr	₹31.00 Cr	₹58.00 Cr	₹56.00 Cr	₹54.00 Cr	₹33.00 Cr	₹45.00 Cr	₹38.00 Cr
EPS in ₹	₹21.54	₹20.95	₹6.32	₹15.79	₹-4.72	₹15.37	₹12.34	₹23.30	₹22.33	₹21.69	₹13.04	₹17.95	₹15.17

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	₹517.00 Cr	₹564.00 Cr	₹544.00 Cr	₹571.00 Cr	₹728.00 Cr	₹832.00 Cr	₹814.00 Cr	₹806.00 Cr	₹1,003 Cr	₹1,296 Cr	₹1,716 Cr	₹2,276 Cr	₹2,432 Cr
Expenses	₹528.00 Cr	₹547.00 Cr	₹506.00 Cr	₹525.00 Cr	₹657.00 Cr	₹711.00 Cr	₹678.00 Cr	₹719.00 Cr	₹838.00 Cr	₹1,111 Cr	₹1,462 Cr	₹2,014 Cr	₹2,202 Cr
Operating Profit	-₹11.00 Cr	₹16.00 Cr	₹37.00 Cr	₹46.00 Cr	₹71.00 Cr	₹121.00 Cr	₹135.00 Cr	₹86.00 Cr	₹165.00 Cr	₹184.00 Cr	₹254.00 Cr	₹262.00 Cr	₹230.00 Cr
OPM %	-2.2%	2.9%	7%	8%	10%	15%	17%	11%	16%	14%	15%	12%	9%
Interest	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹1.00 Cr	₹1.00 Cr	₹1.00 Cr	₹1.00 Cr	₹1.00 Cr	₹1.00 Cr	₹4.00 Cr	₹6.00 Cr
Depreciation	₹15.00 Cr	₹17.00 Cr	₹16.00 Cr	₹15.00 Cr	₹15.00 Cr	₹19.00 Cr	₹20.00 Cr	₹17.00 Cr	₹16.00 Cr	₹15.00 Cr	₹40.00 Cr	₹29.00 Cr	₹17.00 Cr
Profit before Tax	-₹21.00 Cr	₹6.00 Cr	₹36.00 Cr	₹44.00 Cr	₹73.00 Cr	₹114.00 Cr	₹127.00 Cr	₹83.00 Cr	₹134.00 Cr	₹220.00 Cr	₹156.00 Cr	₹252.00 Cr	₹228.00 Cr
Net Profit	-₹21.00 Cr	₹5.00 Cr	₹20.00 Cr	₹26.00 Cr	₹54.00 Cr	₹72.00 Cr	₹93.00 Cr	₹62.00 Cr	₹99.00 Cr	₹162.00 Cr	₹116.00 Cr	₹188.00 Cr	₹170.00 Cr
EPS in Rs	-8.34	2.10	8.02	10.36	21.78	28.88	37.32	24.64	39.72	64.60	46.30	75.01	67.85

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr	₹5.00 Cr
Reserves & Surplus	₹146.00 Cr	₹151.00 Cr	₹218.00 Cr	₹242.00 Cr	₹296.00 Cr	₹359.00 Cr	₹451.00 Cr	₹506.00 Cr	₹584.00 Cr	₹707.00 Cr	₹765.00 Cr	₹868.00 Cr
Borrowings (Debt)	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹0 Cr	₹12.00 Cr	₹12.00 Cr	₹9.00 Cr	₹7.00 Cr	₹5.00 Cr	₹36.00 Cr	₹111.00 Cr
Total Liabilities	₹412.00 Cr	₹403.00 Cr	₹415.00 Cr	₹461.00 Cr	₹562.00 Cr	₹706.00 Cr	₹775.00 Cr	₹857.00 Cr	₹985.00 Cr	₹1,078 Cr	₹1,518 Cr	₹1,989 Cr
Fixed Assets	₹101.00 Cr	₹97.00 Cr	₹87.00 Cr	₹75.00 Cr	₹75.00 Cr	₹72.00 Cr	₹81.00 Cr	₹74.00 Cr	₹69.00 Cr	₹67.00 Cr	₹64.00 Cr	₹117.00 Cr
Total Assets	₹412.00 Cr	₹403.00 Cr	₹415.00 Cr	₹461.00 Cr	₹562.00 Cr	₹706.00 Cr	₹775.00 Cr	₹857.00 Cr	₹985.00 Cr	₹1,078 Cr	₹1,518 Cr	₹1,989 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operations (CFO)	-₹46.00 Cr	₹57.00 Cr	₹38.00 Cr	₹9.00 Cr	₹55.00 Cr	₹87.00 Cr	₹105.00 Cr	₹101.00 Cr	₹58.00 Cr	₹28.00 Cr	₹65.00 Cr	-₹15.00 Cr
Cash from Investing (CFI)	-₹19.00 Cr	-₹4.00 Cr	₹0 Cr	-₹9.00 Cr	₹4.00 Cr	-₹171.00 Cr	₹173.00 Cr	₹5.00 Cr	₹18.00 Cr	₹22.00 Cr	₹31.00 Cr	₹19.00 Cr
Cash from Financing (CFF)	₹0 Cr	-₹1.00 Cr	₹0 Cr	₹0 Cr	₹0 Cr	-₹6.00 Cr	-₹9.00 Cr	-₹9.00 Cr	-₹24.00 Cr	-₹44.00 Cr	-₹66.00 Cr	-₹92.00 Cr
Free Cash Flow (FCF)	-₹69.00 Cr	₹48.00 Cr	₹33.00 Cr	₹3.00 Cr	₹37.00 Cr	₹74.00 Cr	₹99.00 Cr	₹94.00 Cr	₹53.00 Cr	₹18.00 Cr	₹64.00 Cr	-₹18.00 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days (DSO)	30	54	29	35	40	37	38	39	39	43	39	34
Inventory Days	157	141	121	229	186	197	198	164	193	140	208	272
Cash Conversion Cycle (Days)	-16	21	-34	7	-39	-17	15	-20	1	62	74	99
ROCE %	-13%	4%	15%	19%	27%	34%	30%	16%	31%	31%	33%	29%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹1,056.26 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹6,462.50

DCF Fair Value

₹1,056.26

Graham Number

₹736.94

Margin of Safety

-85.9%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹1,056.26

Premium / Overvalued (Margin: -85.9%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹1,028	₹1,019	₹1,009	₹1,000
10%	₹1,047	₹1,037	₹1,028	₹1,019
12%	₹1,066	₹1,056	₹1,047	₹1,037
14%	₹1,085	₹1,075	₹1,065	₹1,056

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹1,056	Fairly Valued
Benjamin Graham Number	₹737	Market Priced
Historical Sector P/E	₹1,522	Premium
EV / EBITDA Multiplier	₹6,786	In-Line
Free Cash Flow Yield Model	₹6,333	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 7/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

7 / 9 Pass

Altman Z-Score

5.41 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.13x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Managing working capital

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 9.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

75.00%

FIIs (Foreign)

2.68%

DIIs (Domestic)

6.08%

Government

0.15%

Public / Retail

16.24%

Swipe → to view historical quarters

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
+ Promoters	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%
+ FIIs (Foreign Portfolio)	2.69%	2.66%	2.73%	2.79%	2.90%	2.92%	2.89%	3.03%	2.74%	2.71%	2.78%	2.68%
+ DIIs (Mutual Funds / Insurance)	2.42%	2.76%	3.77%	4.99%	5.08%	5.21%	4.65%	4.55%	5.26%	5.55%	5.79%	6.08%
+ Public (Retail & HNIs)	19.89%	19.57%	18.50%	17.21%	17.02%	16.85%	17.45%	17.41%	17.00%	16.73%	16.42%	16.24%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

ASTRAZEN Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

ASTRAZEN Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

ASTRAZEN Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹8,272.00

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹7,238.00

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 87x P/E.

🐻 Bear Case (15%) -12.0%

₹5,687.00

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 19:56 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ ASTRAZENECA PHARMA IND LT (ASTRAZEN)	Target Stock	₹6,462.50	-0.80%	86.9x	23.3%	29.3%	0.13	₹15,078 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	19:56:53 IST	✓ Live Sync
Financial Statements (10Y)	ASTRAZENECA PHARMA IND LT Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

ASTRAZENECA PHARMA IND LT

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About ASTRAZENECA PHARMA IND LT

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title